Goldenwell Biotech, Inc. (GWLL) stock
GWLLOTCFood and Kindred ProductsFiscal year ends December 31
$0.65+0.05 (+8.33%)
Close on Oct 19, 2026Market cap $64.35MP/E –Yield –
Goldenwell Biotech operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Goldenwell Biotech's operating income for the twelve months ending Jun 30, 2026 was -$114.80K. For fiscal 2025 it was -$113.33K. The highest annual figure on record is -$113.33K in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$113.33K | – |
| FY2024 | Dec 31, 2024 | -$123.10K | – |
| FY2023 | Dec 31, 2023 | -$115.83K | – |
| FY2022 | Dec 31, 2022 | -$985.11K | – |
| FY2021 | Dec 31, 2021 | -$118.27K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$34.78K | – |
| Q1 FY2026 | Mar 31, 2026 | -$31.34K | – |
| Q4 FY2025 | Dec 31, 2025 | -$22.90K | – |
| Q3 FY2025 | Sep 30, 2025 | -$25.80K | – |
| Q2 FY2025 | Jun 30, 2025 | -$28.20K | – |
| Q1 FY2025 | Mar 31, 2025 | -$36.44K | – |
| Q4 FY2024 | Dec 31, 2024 | -$25.35K | – |
| Q3 FY2024 | Sep 30, 2024 | -$20.97K | – |
| Q2 FY2024 | Jun 30, 2024 | -$47.82K | – |
| Q1 FY2024 | Mar 31, 2024 | -$28.96K | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.80K | – |
| Q3 FY2023 | Sep 30, 2023 | -$35.41K | – |
| Q2 FY2023 | Jun 30, 2023 | -$27.08K | – |
| Q1 FY2023 | Mar 31, 2023 | -$33.61K | – |
| Q4 FY2022 | Dec 31, 2022 | -$920.33K | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.58K | – |
| Q2 FY2022 | Jun 30, 2022 | -$26.80K | – |
| Q1 FY2022 | Mar 31, 2022 | -$33.39K | – |
| Q4 FY2021 | Dec 31, 2021 | -$100.25K | – |
| Q3 FY2021 | Sep 30, 2021 | -$88.71K | – |
See a number that looks wrong?